Glyburide and fetal safety; transplacental pharmacokinetic considerations.

Oral hypoglycemics have been avoided in pregnancy due to their potential to cause fetal hyperinsulinemia/hypoglycemia. A recent human study has shown glyburide to minimally cross the placenta, allowing a safe new treatment for gestational diabetes. The mechanisms for the minimal placental passage of this small molecule are not clear. In this presentation, the role of pKa, molecular weight, lipid solubility, and protein binding is considered. Out of these physical and pharmacologic characteristics, the very extensive plasma protein binding and short elimination half-life of glyburide appear to be major determinants of its minimal transplacental transfer.
AuthorsG Koren
JournalReproductive toxicology (Elmsford, N.Y.) (Reprod Toxicol) 2001 May-Jun Vol. 15 Issue 3 Pg. 227-9 ISSN: 0890-6238 [Print] United States
PMID11390165 (Publication Type: Journal Article, Review)
Chemical References
  • Hypoglycemic Agents
  • Ions
  • Glyburide
  • Adult
  • Female
  • Fetal Diseases (chemically induced)
  • Fetus (drug effects, metabolism)
  • Glyburide (adverse effects, pharmacokinetics)
  • Humans
  • Hypoglycemic Agents (adverse effects, pharmacokinetics)
  • Ions
  • Maternal-Fetal Exchange
  • Molecular Weight
  • Placenta (drug effects, metabolism)
  • Pregnancy
  • Pregnancy Outcome
  • Protein Binding
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: